Do analysts prefer PALI or CPIX?

Palisade Bio currently has a consensus target price of $9.00, suggesting a potential upside of 336.89%. Given Palisade Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Palisade Bio is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palisade Bio 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.00 Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer CPIX or IKT?

Inhibikase Therapeutics has a consensus target price of $5.40, suggesting a potential upside of 130.77%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Inhibikase Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.00

Do analysts recommend CPIX or VNDA?

Vanda Pharmaceuticals has a consensus price target of $13.70, suggesting a potential upside of 169.16%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vanda Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50

Do analysts rate AMRN or CPIX?

Amarin currently has a consensus target price of $13.00, suggesting a potential downside of 5.80%. Given Amarin's stronger consensus rating and higher probable upside, analysts clearly believe Amarin is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33 Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer CPIX or TTRX?

Turn Therapeutics has a consensus target price of $8.00, indicating a potential downside of 36.96%. Given Turn Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Turn Therapeutics is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Turn Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Cumberland Pharmaceuticals (CPIX) Competitors

$6.39 -0.09 (-1.39%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$6.42 +0.03 (+0.41%)

As of 09/11/2026 07:54 PM Eastern

Compare

CPIX vs. PALI, IKT, VNDA, AMRN, and TTRX

Should you buy Cumberland Pharmaceuticals stock or one of its competitors? Cumberland Pharmaceuticals's main competitors and comparable companies include Palisade Bio (PALI), Inhibikase Therapeutics (IKT), Vanda Pharmaceuticals (VNDA), Amarin (AMRN), and Turn Therapeutics (TTRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cumberland Pharmaceuticals compare to Palisade Bio?

Palisade Bio (NASDAQ:PALI) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Palisade Bio has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -34.40%. Cumberland Pharmaceuticals' return on equity of -28.81% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-33.47%	-31.79%
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%

Palisade Bio currently has a consensus target price of $9.00, suggesting a potential upside of 336.89%. Given Palisade Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Palisade Bio is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Palisade Bio had 2 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 3 mentions for Palisade Bio and 1 mentions for Cumberland Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 1.87 beat Palisade Bio's score of 1.63 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Palisade Bio	Very Positive
Cumberland Pharmaceuticals	Very Positive

Palisade Bio has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.13, suggesting that its stock price is 87% less volatile than the broader market.

Cumberland Pharmaceuticals has higher revenue and earnings than Palisade Bio. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,435.98	-$16.78M	-$0.48	N/A
Cumberland Pharmaceuticals	$44.52M	2.15	-$2.84M	-$0.71	N/A

Summary

Palisade Bio beats Cumberland Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Inhibikase Therapeutics?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

Cumberland Pharmaceuticals has higher revenue and earnings than Inhibikase Therapeutics. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	2.15	-$2.84M	-$0.71	N/A
Inhibikase Therapeutics	$260K	1,255.86	-$48.26M	-$0.43	N/A

Inhibikase Therapeutics has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -34.40%. Cumberland Pharmaceuticals' return on equity of -28.81% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%
Inhibikase Therapeutics	N/A	-42.80%	-40.58%

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by company insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cumberland Pharmaceuticals has a beta of 0.13, suggesting that its share price is 87% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

In the previous week, Cumberland Pharmaceuticals and Cumberland Pharmaceuticals both had 1 articles in the media. Inhibikase Therapeutics' average media sentiment score of 1.89 beat Cumberland Pharmaceuticals' score of 1.87 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cumberland Pharmaceuticals	Very Positive
Inhibikase Therapeutics	Very Positive

Inhibikase Therapeutics has a consensus target price of $5.40, suggesting a potential upside of 130.77%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Inhibikase Therapeutics beats Cumberland Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Vanda Pharmaceuticals?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 2 mentions for Vanda Pharmaceuticals and 1 mentions for Cumberland Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 1.87 beat Vanda Pharmaceuticals' score of 1.61 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Cumberland Pharmaceuticals	Very Positive
Vanda Pharmaceuticals	Very Positive

15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are held by insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cumberland Pharmaceuticals has a beta of 0.13, indicating that its share price is 87% less volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

Cumberland Pharmaceuticals has higher earnings, but lower revenue than Vanda Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	2.15	-$2.84M	-$0.71	N/A
Vanda Pharmaceuticals	$216.10M	1.42	-$220.47M	-$4.63	N/A

Vanda Pharmaceuticals has a consensus price target of $13.70, suggesting a potential upside of 169.16%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cumberland Pharmaceuticals has a net margin of -34.40% compared to Vanda Pharmaceuticals' net margin of -127.41%. Cumberland Pharmaceuticals' return on equity of -28.81% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%

Summary

Cumberland Pharmaceuticals and Vanda Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Amarin?

Amarin (NASDAQ:AMRN) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Cumberland Pharmaceuticals has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Cumberland Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.36	-$38.80M	-$0.99	N/A
Cumberland Pharmaceuticals	$44.52M	2.15	-$2.84M	-$0.71	N/A

Amarin currently has a consensus target price of $13.00, suggesting a potential downside of 5.80%. Given Amarin's stronger consensus rating and higher probable upside, analysts clearly believe Amarin is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Amarin has a net margin of -14.56% compared to Cumberland Pharmaceuticals' net margin of -34.40%. Amarin's return on equity of -0.20% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%

In the previous week, Amarin had 1 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 2 mentions for Amarin and 1 mentions for Cumberland Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 1.87 beat Amarin's score of 0.54 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Amarin	Positive
Cumberland Pharmaceuticals	Very Positive

22.3% of Amarin shares are held by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 4.2% of Amarin shares are held by company insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Amarin has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.13, indicating that its share price is 87% less volatile than the broader market.

Summary

Amarin beats Cumberland Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Turn Therapeutics?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Cumberland Pharmaceuticals has higher revenue and earnings than Turn Therapeutics. Turn Therapeutics is trading at a lower price-to-earnings ratio than Cumberland Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	2.15	-$2.84M	-$0.71	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A

Turn Therapeutics has a consensus target price of $8.00, indicating a potential downside of 36.96%. Given Turn Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Turn Therapeutics is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Turn Therapeutics has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -34.40%. Cumberland Pharmaceuticals' return on equity of -28.81% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%
Turn Therapeutics	N/A	-230.84%	-53.19%

In the previous week, Turn Therapeutics had 4 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 5 mentions for Turn Therapeutics and 1 mentions for Cumberland Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 1.87 beat Turn Therapeutics' score of 0.42 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Cumberland Pharmaceuticals	Very Positive
Turn Therapeutics	Neutral

Summary

Cumberland Pharmaceuticals beats Turn Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Cumberland Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPIX vs. The Competition

Export

Metric	Cumberland Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$95.74M	$12.41B	$7.16B	$12.85B
Dividend Yield	N/A	2.63%	2.57%	11.72%
P/E Ratio	-9.00	799.75	274.94	25.36
Price / Sales	2.15	960.74	685.43	116.38
Price / Cash	17.42	88.17	76.65	51.52
Price / Book	3.90	10.39	10.33	6.20
Net Income	-$2.84M	$2.85B	$3.50B	$358.50M
7 Day Performance	-5.89%	-3.61%	-3.32%	-2.35%
1 Month Performance	-19.11%	0.72%	-0.53%	-3.23%
1 Year Performance	85.76%	3.61%	23.51%	8.79%

Cumberland Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPIX Cumberland Pharmaceuticals	0.8914 of 5 stars	$6.39 -1.4%	N/A	+85.8%	$95.74M	$44.52M	N/A	80
PALI Palisade Bio	3.1259 of 5 stars	$1.98 +0.8%	$9.00 +355.7%	+244.5%	$344.18M	$250K	N/A	10	Positive News
IKT Inhibikase Therapeutics	2.2983 of 5 stars	$2.47 +3.6%	$5.40 +119.1%	+50.0%	$343.97M	$260K	N/A	6
VNDA Vanda Pharmaceuticals	3.016 of 5 stars	$5.51 +1.6%	$13.70 +148.9%	+12.9%	$331.62M	$216.10M	N/A	290
AMRN Amarin	0.9435 of 5 stars	$13.71 -1.0%	$13.00 -5.2%	-8.1%	$289.58M	$186.23M	N/A	360

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CPIX) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cumberland Pharmaceuticals (CPIX) Competitors

CPIX vs. PALI, IKT, VNDA, AMRN, and TTRX

How does Cumberland Pharmaceuticals compare to Palisade Bio?

Summary

How does Cumberland Pharmaceuticals compare to Inhibikase Therapeutics?

Summary

How does Cumberland Pharmaceuticals compare to Vanda Pharmaceuticals?

Summary

How does Cumberland Pharmaceuticals compare to Amarin?

Summary

How does Cumberland Pharmaceuticals compare to Turn Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPIX vs. The Competition

Cumberland Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cumberland Pharmaceuticals (CPIX) Competitors

CPIX vs. PALI, IKT, VNDA, AMRN, and TTRX

How does Cumberland Pharmaceuticals compare to Palisade Bio?

Do insiders and institutionals hold more shares of PALI or CPIX?

Is PALI or CPIX more profitable?

Do analysts prefer PALI or CPIX?

Does the media prefer PALI or CPIX?

Which has more volatility and risk, PALI or CPIX?

Which has stronger valuation & earnings, PALI or CPIX?

Summary

How does Cumberland Pharmaceuticals compare to Inhibikase Therapeutics?

Which has higher valuation and earnings, CPIX or IKT?

Is CPIX or IKT more profitable?

Do institutionals and insiders hold more shares of CPIX or IKT?

Which has more volatility & risk, CPIX or IKT?

Does the media prefer CPIX or IKT?

Do analysts prefer CPIX or IKT?

Summary

How does Cumberland Pharmaceuticals compare to Vanda Pharmaceuticals?

Does the media favor CPIX or VNDA?

Do insiders and institutionals hold more shares of CPIX or VNDA?

Which has more volatility & risk, CPIX or VNDA?

Which has stronger earnings and valuation, CPIX or VNDA?

Do analysts recommend CPIX or VNDA?

Is CPIX or VNDA more profitable?

Summary

How does Cumberland Pharmaceuticals compare to Amarin?

Which has preferable earnings & valuation, AMRN or CPIX?

Do analysts rate AMRN or CPIX?

Is AMRN or CPIX more profitable?

Does the media refer more to AMRN or CPIX?

Do insiders & institutionals have more ownership in AMRN or CPIX?

Which has more volatility & risk, AMRN or CPIX?

Summary

How does Cumberland Pharmaceuticals compare to Turn Therapeutics?

Which has better valuation and earnings, CPIX or TTRX?

Do analysts prefer CPIX or TTRX?

Do insiders and institutionals believe in CPIX or TTRX?

Is CPIX or TTRX more profitable?

Does the media prefer CPIX or TTRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPIX vs. The Competition

Cumberland Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools